When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALLK - Allakos' lead candidate shows positive effect in mid-stage hives study
Allakos Inc.
An open-label Phase 2 clinical trial evaluating Allakos' (NASDAQ:ALLK) lead drug AK002 in 11 patients with chronic spontaneous urticaria (hives) who failed to respond to Roche and Novartis' Xolair (omalizumab) after an average of 10 months' treatment showed a positive effect.